Evonile Pharma
BSE 500672
15 stories, newest first.
- Evonile Pharma reports first results after change of control
- Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
- Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
- BSE in-principle approval received for proposed rights issue of up to ₹9,000.00 million
- BSE in-principle approval for rights issue; board to take up Letter of Offer on November 04, 2026
- Earnings call on November 04, 2026 to discuss Q2 and half-year FY2026-27 results
- Gagan Sharma designated Senior Management Personnel as President – Specialty Business
- Board approves fund raise of up to ₹9,000 million via rights issue of partly paid-up equity shares
- Board approves rights issue of partly paid-up equity shares up to ₹9,000 million
- Board approves rights issue of up to ₹9,000 million, constitutes Rights Issue Committee
- CARE A; Stable assigned to Evonile Pharma's long-term bank facilities, CARE A2+ for short-term
- Board meeting on October 08, 2026 to consider fund-raise via rights issue of equity shares
- Name changed to Evonile Pharma Limited with effect from October 01, 2026; fresh Certificate of Incorporation issued
- Company name changed from Novartis India Limited to Evonile Pharma Limited with effect from October 01, 2026
- Board Meeting on November 3, 2026 for Q2 and Half-Year Results; Trading Window Closed
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.